AN2 Therapeutics, Inc. Net Income
AN2 Therapeutics, Inc. (ANTX) reported Net Income of -$8.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-11
- AN2 Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$8.19M.
- AN2 Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$10.03M.
- AN2 Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$8.67M.
- AN2 Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$9.35M.
- AN2 Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2025 was -$35.17M.
- AN2 Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2024 was -$51.32M.
- AN2 Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2023 was -$64.73M.
- AN2 Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$40.96M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$8.19M 10-Q · filed 2026-08-11 | -$18.20M 10-Q · filed 2026-08-11 | -$26.89M derived: sum of 3 quarters · filed 2026-08-11 | -$36.24M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$10.03M 10-Q · filed 2026-08-11 | -$18.70M derived: sum of 2 quarters · filed 2026-08-11 | -$28.05M derived: sum of 3 quarters · filed 2026-08-11 | -$34.52M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$18.03M derived: sum of 2 quarters · filed 2026-03-17 | -$24.49M derived: sum of 3 quarters · filed 2026-08-11 | -$35.17M 10-K · filed 2026-03-17 | |
| 2025-09-30 | -$9.35M 10-Q · filed 2025-11-12 | -$15.81M derived: sum of 2 quarters · filed 2026-08-11 | -$26.50M 10-Q · filed 2025-11-12 | -$33.98M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$6.46M 10-Q · filed 2026-08-11 | -$17.10M 10-Q · filed 2026-08-11 | -$24.63M derived: sum of 3 quarters · filed 2026-08-11 | -$37.38M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$10.65M 10-Q · filed 2026-08-11 | -$18.17M derived: sum of 2 quarters · filed 2026-08-11 | -$30.92M derived: sum of 3 quarters · filed 2026-08-11 | -$45.35M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2024-12-31 | -$7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$20.27M derived: sum of 2 quarters · filed 2026-03-17 | -$34.70M derived: sum of 3 quarters · filed 2026-03-17 | -$51.32M 10-K · filed 2026-03-17 | |
| 2024-09-30 | -$12.75M 10-Q · filed 2025-11-12 | -$27.18M derived: sum of 2 quarters · filed 2025-11-12 | -$43.80M 10-Q · filed 2025-11-12 | -$60.73M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$14.44M 10-Q · filed 2025-11-12 | -$31.10M 10-Q · filed 2025-08-12 | -$47.98M derived: sum of 3 quarters · filed 2025-11-12 | -$64.69M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-03-31 | -$16.62M 10-Q · filed 2025-11-12 | -$33.55M derived: sum of 2 quarters · filed 2025-11-12 | -$50.26M derived: sum of 3 quarters · filed 2025-11-12 | -$66.06M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2023-12-31 | -$16.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$33.64M derived: sum of 2 quarters · filed 2025-03-25 | -$49.44M derived: sum of 3 quarters · filed 2025-03-25 | -$64.73M 10-K · filed 2025-03-25 | |
| 2023-09-30 | -$16.71M 10-Q · filed 2024-11-13 | -$32.51M derived: sum of 2 quarters · filed 2024-11-13 | -$47.80M 10-Q · filed 2024-11-13 | -$47.83M 10-Q · filed 2023-11-09 | -$59.68M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$15.80M 10-Q · filed 2024-11-13 | -$31.13M 10-Q · filed 2023-08-10 | -$42.97M derived: sum of 3 quarters · filed 2024-11-13 | -$54.31M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-03-31 | -$15.32M 10-Q · filed 2024-11-13 | -$27.16M derived: sum of 2 quarters · filed 2024-11-13 | -$38.50M derived: sum of 3 quarters · filed 2024-11-13 | -$48.62M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2022-12-31 | -$11.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$23.18M derived: sum of 2 quarters · filed 2024-03-29 | -$33.30M derived: sum of 3 quarters · filed 2024-03-29 | -$40.96M 10-K · filed 2024-03-29 | |
| 2022-09-30 | -$11.34M 10-Q · filed 2023-11-09 | -$21.46M derived: sum of 2 quarters · filed 2023-11-09 | -$29.11M 10-Q · filed 2023-11-09 | -$36.66M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$10.12M 10-Q · filed 2023-11-09 | -$17.77M 10-Q · filed 2023-08-10 | -$25.32M derived: sum of 3 quarters · filed 2023-11-09 | -$32.26M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-03-31 | -$7.66M 10-Q · filed 2023-11-09 | -$15.20M derived: sum of 2 quarters · filed 2023-11-09 | -$22.14M derived: sum of 3 quarters · filed 2023-11-09 | -$27.15M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2021-12-31 | -$7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$14.49M derived: sum of 2 quarters · filed 2023-03-29 | -$19.50M derived: sum of 3 quarters · filed 2023-03-29 | -$21.54M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$6.94M 10-Q · filed 2022-11-09 | -$11.95M derived: sum of 2 quarters · filed 2022-11-09 | -$14.00M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$5.01M 10-Q · filed 2022-11-09 | -$7.05M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$2.05M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |